How to buy NextCure  stock (NXTC)

NextCure  is a biotechnology business based in the US. NextCure  shares (NXTC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.82 – a decrease of 15.46% over the previous week. NextCure  employs 82 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy NextCure  stock

Buy NextCure  stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

NextCure  stock price (NASDAQ: NXTC)

Use our graph to track the performance of NXTC stocks over time.

NextCure  shares at a glance

• Key figures

Information last updated 2024-12-25.

Latest market close	$0.82
52-week range	$0.84 - $2.57
50-day moving average more info button	$1.23
200-day moving average more info button	$1.49
Wall St. target price	$3.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.10

Is it a good time to buy NextCure  stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NextCure  price performance over time

Historical closes compared with the close of $0.8278 from 2024-12-26

1 week (2024-12-20)	-14.66%
1 month (2024-11-27)	-29.25%
3 months (2024-09-27)	-40.01%
6 months (2024-06-28)	-47.94%

1 year (2023-12-28)	-28.02%
2 years (2022-12-28)	-33.78%
3 years (2021-12-28)	5.96
5 years (2019-12-27)	58.71

NextCure  financials

Gross profit TTM	$-54,199,000
Return on assets TTM	-31.09%
Return on equity TTM	-54.75%
Profit margin	0%
Book value	$4.10
Market Capitalization more info button	$24.3 million

TTM: trailing 12 months

NextCure  share dividends

We're not expecting NextCure  to pay a dividend over the next 12 months.

NextCure  share price volatility

Over the last 12 months, NextCure 's shares have ranged in value from as little as $0.843 up to $2.57. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NextCure 's is 0.791. This would suggest that NextCure 's shares are less volatile than average (for this exchange).

NextCure  overview

NextCure, Inc. , a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. .

Frequently asked questions

What percentage of NextCure  is owned by insiders or institutions?
Currently 8.853% of NextCure  shares are held by insiders and 57.52% by institutions. How many people work for NextCure ?
Latest data suggests 82 work at NextCure . When does the fiscal year end for NextCure ?
NextCure 's fiscal year ends in December. Where is NextCure  based?
NextCure 's address is: 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 What is NextCure 's ISIN number?
NextCure 's international securities identification number is: US65343E1082 What is NextCure 's CUSIP number?
NextCure 's Committee on Uniform Securities Identification Procedures number is: 65343E108